ProCE Banner Activity

Key Points in the Management of Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Clinical Thought
Expert faculty discuss how they treat NF1 and inoperable PNs and key points they want you to know.

Released: July 18, 2022

Expiration: July 17, 2023

No longer available for credit.

Share

Faculty

Miriam Bornhorst

Miriam Bornhorst, MD

Clinical Director 
Gilbert Neurofibromatosis Clinic
Medical Director 
Cancer Genetics Clinic
Attending Neuro-oncologist
Department of Neurology and Oncology
Center for Genetics Medicine Research
Children's National Hospital
Assistant Professor of Pediatrics
George Washington University
Washington, D.C.

Carlos Romo

Carlos Romo, MD

Assistant Professor of Neurology, Oncology and Medicine Director of Clinical Research
The Neurofibromatosis Therapeutic Acceleration Program
Department of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Alexion Pharmaceuticals

Faculty Disclosure

Primary Author

Miriam Bornhorst, MD

Clinical Director 
Gilbert Neurofibromatosis Clinic
Medical Director 
Cancer Genetics Clinic
Attending Neuro-oncologist
Department of Neurology and Oncology
Center for Genetics Medicine Research
Children's National Hospital
Assistant Professor of Pediatrics
George Washington University
Washington, D.C.

Miriam Bornhorst, MD, has no relevant financial relationships to disclose.

Carlos Romo, MD

Assistant Professor of Neurology, Oncology and Medicine Director of Clinical Research
The Neurofibromatosis Therapeutic Acceleration Program
Department of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Carlos Romo, MD, has no relevant financial relationships to disclose.